Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyMax S. Topp, Jennifer L. Crombie, Jeffrey A. Barnes et al.|Blood|2024Cited by 28
LGR6 promotes glioblastoma malignancy and chemoresistance by activating the Akt signaling pathwayYuan Cheng, Fang Xie|Experimental and Therapeutic Medicine|2021Cited by 11
Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 StudiesJohn N. Allan, Jon Arnason, Jennifer L. Crombie et al.|Blood|2024Cited by 6